Voriconazole
Find information on thousands of medical conditions and prescription drugs.

Vfend

Voriconazole (Vfend®, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These infections include invasive candidiasis and aspergillosis. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Administration

Oral (in tablets or suspension) or intravenous. Voriconzole interacts with many medications, including drugs given to suppress the immune system in transplant patients (e.g. cyclosporine, etc.).

Side effects

Common side effects include:

  • Blurred vision, increased eye sensitivity to light, or other visual changes
  • Nausea, vomiting, or diarrhea
  • Headache
  • Swelling or water retention.

Rare but life-threatening side effects include:

  • Severe liver damage
  • Allergic reactions to the medication

Read more at Wikipedia.org


[List your site here Free!]


Powerful drug approved for fatal fungal infections
From Nursing, 9/1/02

VFEND

A new antifungal drug, Wend (voriconazole), has been approved by the FDA for life-threatening systemic fungal infections. Available in both IN. and oral forms, the drug is indicated for primary treatment of acute invasive aspergillosis and as salvage therapy for rare but serious fungal infections caused by the pathogens Scedosporium apiospermum and Fusarium species that have resisted other therapies. Amphotericin B is currently the standard treatment for systemic fungal infections.

In a large clinical trial, Wend proved more effective than amphotericin B as primary treatment for invasive aspergillosis. Fifty-three percent of patients who received Wend had responded at 12 weeks of treatment, versus 32% of those who received amphotericin B. The survival rate for Wend-treated patients was 71%, compared with 58% of those in the amphotericin B arm of the study.

Unlike amphotericin B, Wend is generally well tolerated. The most common adverse reactions reported among patients during clinical trials were visual disturbances, elevations of liver function tests, and skin rash. For most patients, these were mild to moderate in severity and usually didn't result in discontinuation of treatment. The option of oral administration permits flexibility in patient care, including step-down therapy during recovery.

Wend is a product of Pfizer, Inc.

Copyright Springhouse Corporation Sep 2002
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Vfend
Home Contact Resources Exchange Links ebay